



## Genflow Biosciences Plc to Present at the Life Sciences Investor Forum September 19th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at [VirtualInvestorConferences.com](https://VirtualInvestorConferences.com)

Your publication date and time will appear here.

| Source: [Virtual Investor Conferences](#)

LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- **Genflow Biosciences Plc** (LSE:GENF OTCQB:GENFF), based in the UK, focused on pioneering gene therapies to decelerate the aging process, today announced that Dr Eric Leire, Chief Executive Officer, will present live at the Life Sciences Investor Forum, hosted by [VirtualInvestorConferences.com](https://VirtualInvestorConferences.com), on September 19<sup>th</sup> 2024.

**DATE:** September 19<sup>th</sup>

**TIME:** 10:00 AM ET

**LINK:** <https://bit.ly/3XjDJkL>

Available for 1x1 meetings: September 19

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at [www.virtualinvestorconferences.com](https://www.virtualinvestorconferences.com).

### **About Genflow Biosciences Plc**

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with

Share



the goal of promoting longer and healthier lives while mitigating the financial, emotional and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

**About Virtual Investor Conferences®**

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

**CONTACTS:**

**Genflow Biosciences**

Jonathan Paterson

Investor Relations

+1 475 477 9401

[Jonathan.Paterson@Harbor-Access.com](mailto:Jonathan.Paterson@Harbor-Access.com)

**Virtual Investor Conferences**

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

[johnv@otcmarkets.com](mailto:johnv@otcmarkets.com)